Mobile

A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy

Mise à jour : Il y a 4 ans
Référence : NCT00936546

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

This study will evaluate the safety and efficacy of the combination of rituximab and methotrexate to treat disabling fibrosing skin disorders.Rituximab will be administered at baseline and month 6. The drug will be considered efficacious if the skin thickness diminishes substantially.

Critère d'inclusion

  • Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)

Liens